Written Answers - Medical Cards

Tuesday, 28 February 2012

Dáil Éireann Debate
Vol. 757 No. 1

First Page Previous Page Page of 540 Next Page Last Page

  674.  Deputy Sean Fleming  Information on Seán Fleming  Zoom on Seán Fleming   asked the Minister for Health  Information on Dr James Reilly  Zoom on Dr James Reilly   when a medical card will be granted to a person (details supplied) in County Laois; and if he will make a statement on the matter. [10811/12]

Minister of State at the Department of Health (Deputy Róisín Shortall): Information on Róisín Shortall  Zoom on Róisín Shortall  As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.

  675.  Deputy Sean Fleming  Information on Seán Fleming  Zoom on Seán Fleming   asked the Minister for Health  Information on Dr James Reilly  Zoom on Dr James Reilly   when a medical card will be provided to persons (details supplied) in County Laois; and if he will make a statement on the matter. [10815/12]

Minister of State at the Department of Health (Deputy Róisín Shortall): Information on Róisín Shortall  Zoom on Róisín Shortall  As this is a service matter it has been referred to the Health Service Executive for direct reply to the Deputy.

  676.  Deputy Marcella Corcoran Kennedy  Information on Marcella MarcellaCorcoran Kennedy  Zoom on Marcella MarcellaCorcoran Kennedy   asked the Minister for Health  Information on Dr James Reilly  Zoom on Dr James Reilly   the reason a drug generally available to medical card holders has not been made available to a person (detail supplied) in County Offaly; and if he will make a statement on the matter. [10820/12]

Minister of State at the Department of Health (Deputy Róisín Shortall): Information on Róisín Shortall  Zoom on Róisín Shortall  Pradaxa is available under the GMS Scheme, the Drug Payment Scheme and other community drugs schemes for the prevention of blood clots in adult patients who have undergone elective hip replacement surgery or elective knee replacement surgery.

The HSE is assessing the availability of resources to provide for the long term treatment with Pradaxa for the prevention of stroke in patients with atrial fibrillation. This is a complicated process with long term implications.

The HSE wrote to all GMS doctors and community pharmacy contractors in November 2011 to clarify the position in relation to Pradaxa. The HSE will continue to update healthcare professionals in relation to the matter.

The HSE does not intend to disturb established therapeutic regimens for patients whose treatment with Pradaxa for the prevention of stroke was initiated prior to the clarification.


Last Updated: 08/03/2013 14:47:47 First Page Previous Page Page of 540 Next Page Last Page